Brief: Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio
02/06/2025 13:20
June 2 (Reuters) - Trevi Therapeutics Inc TRVI.O: TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 2B CORAL TRIAL OF HADUVIO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS CHRONIC COUGH TREVI THERAPEUTICS INC - TO REQUEST END-OF-PHASE 2 MEETING WITH FDA, PHASE 3 IN 2026 TREVI THERAPEUTICS INC - HADUVIO MET PRIMARY ENDPOINT , ACHIEVES -43.3% PLACEBO-ADJUSTED CHANGE IN COUGH FREQUENCY AT 108 MG BID TREVI THERAPEUTICS INC - HADUVIO WELL-TOLERATED WITH SIMILAR DISCONTINUATION RATES TO PLACEBO Source text: ID:nPn2bbxFCa Further company coverage: TRVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million